Intervention not reported
Surgical excision versus laser vaporisationor other · women with usual‐type vulval intraepithelial neoplasia
1 finding from 1 review
Intervention not reported
Photodynamic therapy versus laser vaporisationand surgical excision · women with usual‐type vulval intraepithelial neoplasia
1 finding from 1 review
Intervention not reported
LEEP versus laser vaporisation and surgical excision · women with usual‐type vulval intraepithelial neoplasia
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review
Intervention not reported
Direct surgical morbidity · women with stage I endometrial cancer
The intervention showed no clear difference in direct surgical morbidity (moderate certainty).
1 finding from 1 review
Intervention not reported
Cognitive function using validated neuropsychological tests · patients with a primary brain tumour, within two weeks of surgical intervention
1 finding from 1 review
Response to treatment at 5 to 6 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ overall response compared with placebo (high certainty).
1 finding from 1 review
Complete response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in response to treatment at 6 months ‐ complete response compared with cidofovir (moderate certainty).
1 finding from 1 review
Pain ‐ Any grade · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in pain ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Fatigue · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher fatigue ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Headache · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher headache ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
1 finding from 1 review
Treatment discontinuation · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in treatment discontinuation compared with cidofovir (moderate certainty).
1 finding from 1 review
Intervention not reported
Laser vaporisation versus CUSA · women with usual‐type vulval intraepithelial neoplasia
The intervention showed no clear difference in laser vaporisation versus CUSA (low certainty).
1 finding from 1 review
Complete response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ complete response compared with placebo (high certainty).
2 findings from 1 review
Response to treatment at 12 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher response to treatment at 12 months ‐ overall response compared with placebo (moderate certainty).
1 finding from 1 review
Progression to vulval cancer at 12 months · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in progression to vulval cancer at 12 months compared with placebo (low certainty).
1 finding from 1 review